Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 5,746 | 703 | 4,979 |
| Samples | 1,744 | 305 | 1,415 |
| Peptides | 1,366 | 212 | 1,190 |
Function
PEG3 · Paternally expressed 3
In human, ZIM2 and PEG3 are treated as two distinct genes though they share multiple 5' exons and a common promoter and both genes are paternally expressed (PMID:15203203). Alternative splicing events connect their shared 5' exons either with the remaining 4 exons unique to ZIM2, or with the remaining 2 exons unique to PEG3. In contrast, in other mammals ZIM2 does not undergo imprinting and, in mouse, cow, and likely other mammals as well, the ZIM2 and PEG3 genes do not share exons. Human PEG3 protein belongs to the Kruppel C2H2-type zinc finger protein family. PEG3 may play a role in cell proliferation and p53-mediated apoptosis. PEG3 has also shown tumor suppressor activity and tumorigenesis in glioma and ovarian cells. Alternative splicing of this PEG3 gene results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Sep 2009].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 1315 amino-acid changes on canonical ENST00000326441 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PEG3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PEG3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 6/26 23% | 0/0 0% |
| Melanoma | 31/210 15% | 246/1899 13% |
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 15/57 26% | 76/810 9% |
| Non-Small Cell Lung Carcinoma | 46/304 15% | 114/1390 8% |
| Oral Cavity Carcinoma | 5/54 9% | 0/0 0% |
| Endometrial Carcinoma | 13/42 31% | 43/612 7% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Acute Myeloid Leukemia | 6/90 7% | 0/0 0% |
| Other Solid Cancers | 7/94 7% | 93/1515 6% |
| Colorectal Carcinoma | 33/143 23% | 176/3239 5% |
| Gastric Carcinoma | 9/74 12% | 102/1809 6% |
| Small Cell Lung Carcinoma | 1/9 11% | 40/752 5% |
| Neuroendocrine Tumour | 24/154 16% | 13/577 2% |
| Chordoma | 1/7 14% | 0/13 0% |
| Esophageal Carcinoma | 3/23 13% | 31/769 4% |
| Bladder Carcinoma | 3/58 5% | 39/956 4% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Esophageal Squamous Cell Carcinoma | 6/51 12% | 85/2550 3% |
| Head and Neck Carcinoma | 8/85 9% | 48/1574 3% |
| Germ Cell Tumour | 5/25 20% | 1/169 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Other Sarcomas | 9/69 13% | 14/699 2% |
| Cervical Carcinoma | 3/35 9% | 10/422 2% |
| Pancreatic Carcinoma | 6/89 7% | 41/1611 3% |
| Ovarian Carcinoma | 2/109 2% | 27/998 3% |
| Hepatocellular Carcinoma | 2/46 4% | 49/2210 2% |
| Non-Cancerous | 3/104 3% | 15/830 2% |
| Biliary Tract Carcinoma | 0/54 0% | 17/950 2% |
| Plasma Cell Myeloma | 4/44 9% | 1/305 0% |
Mutation Distribution
Where PEG3 is mutated · all tissues, split by cell line vs tissue
How many mutations in PEG3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 5,746 mutations in PEG3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|